Literature DB >> 11781403

Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

G C Pope1, C J Urato, E D Kulas, R Kronick, T Gilmer.   

Abstract

OBJECTIVE: To determine the prevalence, expenditures, and utilization of enrollees with MS relative to all enrollees in privately insured, Medicare, and Medicaid populations.
METHODS: The authors used insurer administrative billing data to identify persons with MS, their insured medical expenditures and utilization, and benchmark general insured population expenditures and utilization. Three samples of insurer billing data were analyzed: nationally representative samples for the privately insured (1994 through 1995) and Medicare (1996 though 1997) populations, and Medicaid data for disabled (1991 through 1996) populations from six states.
RESULTS: Using 2 years of diagnoses on claims, the prevalence of MS in the privately insured population was 24 per 10,000, 36 per 10,000 in the Medicare population, and 71 per 10,000 in the Medicaid disabled population. Annual insured expenditures were $7,677 per privately insured enrollee with MS vs $2,394 for all privately insured enrollees, $13,048 per Medicare beneficiary with MS compared with $6,006 for all Medicare beneficiaries, and $7,352 per Medicaid disabled recipient with MS vs $4,088 per disabled recipient without MS. Home health expenditures were very high for Medicare beneficiaries with MS and nursing facility expenditures were very high for Medicaid disabled recipients with MS. A small proportion of enrollees with MS accounted for most expenditures.
CONCLUSIONS: Insured enrollees with MS are two to three times more expensive than average insured enrollees. If the premiums that employers or governments pay health insurers and the capitation amounts that insurers pay health care providers do not account for these higher costs, a disincentive is created for the enrollment and care of persons with MS.

Entities:  

Mesh:

Year:  2002        PMID: 11781403     DOI: 10.1212/wnl.58.1.37

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Neurologic disorders in Medicaid vs privately insured children and working-age adults.

Authors:  Farrah J Mateen; Joseph P Geer; Kevin Frick; Marco Carone
Journal:  Neurol Clin Pract       Date:  2014-04

Review 3.  Economic burden of multiple sclerosis: a systematic review of the literature.

Authors:  Huseyin Naci; Rachael Fleurence; Julie Birt; Amy Duhig
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  The direct cost of patients with multiple sclerosis: a survey from Italian MS centres.

Authors:  Berto P; Amato M P; Bellantonio P; Bortolon F; Cavalla P; Florio C; Lugaresi A; Montanari E; Rottoli M; Simone I L; Zaffaroni M
Journal:  Neurol Sci       Date:  2011-04-20       Impact factor: 3.307

Review 5.  Early intervention in multiple sclerosis : better outcomes for patients and society?

Authors:  Peter Flachenecker; Peter Rieckmann
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

7.  Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Authors:  Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

8.  Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors:  Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

9.  Feasibility of creating a National ALS Registry using administrative data in the United States.

Authors:  Wendy E Kaye; Marchelle Sanchez; Jennifer Wu
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-03-06       Impact factor: 4.092

10.  Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.

Authors:  Cathryn A Carroll; Kathleen A Fairman; Maureen J Lage
Journal:  BMC Health Serv Res       Date:  2014-07-02       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.